Skip to content

Trait absorption association with ketamine’s benefits and drug-context interactions in treatment-resistant depression: exploratory results from the MUSIK randomized clinical trial

Nicolas Garel, Sara de la Salle, Julien Thibault Lévesque, Alyssa Bensoussan, Juliette Vaugeois, David Erritzøe, Soham Rej, Michael Lifshitz, Stephane Richard-Devantoy, Kyle T. Greenway

Communications medicine November 14, 2026 DOI: 10.1038/s43856-026-01987-8 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Exploratory secondary analysis of a multi-site, parallel, single-blind randomized controlled trial Peer reviewed
Sample size 32
Population Adults aged 18-75 years with severe treatment-resistant depression
Interventions Ketamine music-based support mindfulness-based support
Dose 0.5 mg/kg over 40 min, six infusions
Duration Six infusions over four weeks
Measures Mystical Experience Questionnaire
Topics Depression Esketamine Ketamine
Registration NCT04701866
Key findings Higher baseline trait absorption was associated with larger improvements in depression, anxiety, and suicidality, and with higher mystical-type experience scores during ketamine therapy. Music-based support, compared with matched non-music support, was associated with greater depression improvement among higher-absorption individuals. The authors suggest these findings may help guide patient selection and personalized use of music or mindfulness in ketamine therapy, pending confirmation in larger studies.

Abstract

Ketamine exerts rapid antidepressant effects in treatment-resistant depression (TRD) but therapeutic predictors remain elusive. The personality trait absorption – tendencies for immersive sensory, imaginative, and emotional experiences – influences responses to serotonergic psychedelics, like psilocybin, but has not been studied for ketamine. This study explores trait absorption’s influences on ketamine-therapy for TRD, including interactions with music- versus mindfulness-based support. This exploratory analysis draws on the MUSIK trial (NCT04701866), a multi-site, parallel, single-blind RCT at two Montreal hospitals, whose primary outcome examined hemodynamic effects of pairing ketamine with music. Thirty-two adults (aged 18-75 years) with severe TRD, receiving a structured psychedelic ketamine-therapy intervention, were randomized 1:1 to receive either music (n = 15) or matched non-music support (n = 17) during their six infusions (0.5 mg/kg over 40 min) over four weeks. Outcome assessors but not participants were blinded. Across 181 infusions, this exploratory outcome examined associations between baseline absorption and (1) changes in depression, anxiety, and suicidality; and (2) mystical/emotional experiences using linear correlations and multilevel models. Baseline trait absorption is associated (p ≤ .002) with pre-post improvements in depression (r = .721), anxiety (r = .546), and mean/peak Mystical Experience Questionnaire scores (r = .528-.637). In multilevel models, higher absorption is associated with steeper declines in depression and suicidality. Three-way interactions with timepoint and group suggest that music, versus matched non-music support, is associated with greater depression improvements in higher-absorption individuals (p <.001). Although confirmation in larger studies is required, this exploratory study suggests that trait absorption relates to ketamine’s benefits for TRD. Observed drug-context interactions highlight possible strategies for individuallytailoring ketamine-therapy. Low-dose ketamine can be very beneficial for severe depression even when other treatments have not helped. However, much remains unknown about how ketamine works and who might most benefit. This study explored how a personality trait called absorption may influence the benefits of a series of ketamine doses, paired with either music- or mindfulness-based support, for adults with severe depression. Trait absorption reflects an individual’s tendencies to become deeply immersed in sensory, imaginative, and emotional experiences. The results suggest that higher trait absorption is associated with greater benefits from ketamine, especially when administered with music. This may be because high-absorption individuals tend to have more significant ketamine experiences – indeed, the study found that higher trait absorption was associated with more mystical-like ketamine experiences. If confirmed, these results may help guide patient selection and the personalized use of mindfulness or music in ketamine therapy for depression. Garel et al. explore the influence of the personality trait absorption in the MUSIK trial which administered 181 doses of ketamine, with either music or mindfulness, for treatment-resistant depression. Higher absorption is associated with larger antidepressant effects, reduced suicidality, and more mystical experiences, especially with music-based support.

Comparable studies

Other randomized controlled trials on ketamine, most cited first.

Study Year Design Participants
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Healthy human subjects recruited from the community 1994 Randomized controlled trial n = 19
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial Patients with treatment-resistant major depression experiencing a major depressive episode 2013 Randomized controlled trial n = 73
Remifentanil-induced Postoperative Hyperalgesia and Its Prevention with Small-dose Ketamine Patients undergoing major abdominal surgery 2005 Randomized controlled trial n = 75
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder Patients with chronic PTSD related to a range of trauma exposures 2014 Randomized controlled trial n = 41
Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers Healthy volunteers 2000 Single-blind placebo-controlled study n = 20

Explore topics